Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Poll|Slideshows|May 16, 2025
- Pharmaceutical Executive: May 2025
- Volume 45
- Issue 4
Pharm Exec's 2025 State of the Industry Survey
Author(s)Michael Christel
Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.
Advertisement
Advertisement
Pharmaceutical Executive recently conducted an in-depth survey on the current landscape and potential outlook for the life sciences industry, drawing valuable feedback from top decision-makers in biopharma.
Related to this article
Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
CGT commercial trajectories are set years before approval — and every development decision is an access decision.
Inizio's Elaine Ferguson on why AI value requires deconstructing workflows task by task — aligning each to the right combination of talent and technology.
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Inizio's Elaine Ferguson on why connecting talent across 10,500 employees and four business units is fundamental to delivering client value.
Advertisement
Advertisement